Clinical Trial Update: Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria [Phase 1]

View source ↗

Summary

Phase 1 trial of an investigational RNA-based malaria vaccine by BioNTech assessed safety and immune responses; study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• RNA-based malaria vaccine (RNA-based malaria vaccine)

Snippet

Sponsor: BioNTech SE | Conditions: Malaria | Phase 1 | Status: COMPLETED | Results posted: 2025-09-03